November 2024 — Monthly Briefing¶
1. What was read¶
870 research articles from 32 of the 33 journals on the roster.
A further 313 records (26% of the 1,183 this month's harvest returned) carry no abstract and are not research: news, correspondence, editor highlights and obituaries. PubMed types them Journal Article and nothing else, so the publication-type filter cannot see them — across the whole index they are 22.7% of it and 35% of general, and 3,801 of them are JAMA. Every count below is over the full harvest and is inflated by this; the figure above is not.
| General | Cancer | Immune | Bioinfo | Sysbio |
|---|---|---|---|---|
| 537 | 221 | 79 | 322 | 24 |
Largest contributors: JAMA 122, Bioinformatics 109, Science 106, Nature 98, Nucleic Acids Res 90, Lancet 58.
2. Net change on the thread curve¶
| Thread | This month | Cumulative | Status |
|---|---|---|---|
agentic-ai |
+1 | +6 / −0 | forming |
cell-therapy |
+5 / −1 | +141 / −43 | forming |
ctdna-mrd |
+1 | +45 / −22 | forming |
foundation-models |
+2 / −3 | +69 / −48 | splitting |
immunotherapy-resistance |
+2 / −1 | +148 / −61 | forming |
interception |
+5 / −1 | +82 / −17 | forming |
method-credibility |
+3 / −17 | +10 / −296 | crisis |
neoantigen-vaccines |
+1 | +55 / −23 | forming |
neuro-immune-microbiome-axis |
+3 | +105 / −13 | forming |
next-gen-checkpoints |
+1 | +49 / −30 | splitting |
single-cell-3d-genome |
+3 | +48 / −15 | forming |
suppressive-population-inversion |
— | +34 / −45 | contested |
Status is derived by rule, not asserted. Fewer than 5 cards → too-early; then refutes ≥ 2×supports → crisis; refutes > supports → contested; supports ≥ 2×refutes → forming; else splitting.
3. The evidence that moved it¶
The pretrained component is removed, and the method still works. 39384986 (Nat Methods): de novo protein design with a denoising diffusion network independent of pretrained structure-prediction models. The foundation-model thread's claim is that scale and pretraining produce transferable general-purpose models. A title announcing independence from pretraining as the contribution is the cleanest available refutation of that claim, and it is a constructive one — the ablation is the result.
A generalist biomedical vision-language model. 39112796 (Nat Med) runs in the other direction in the same month. November 2024 has both the generalist claim and its ablation.
39546375: an agent pointed at a working scientist's own data. LmRaC lets an LLM interrogate user experimental results. The agentic thread's claim is about research infrastructure rather than demonstrations, and a tool that takes a user's own unpublished results as input is infrastructure by that definition.
4. Refutations¶
(a) Landing on a tracked thread¶
The diffusion-without-pretraining paper above is filed on foundation-models, and
it is one of six refutations on tracked threads this month. Two more land on the
same thread, and both are about deployment rather than about models:
39122964 (Nat Med) — in a
randomised double-blind trial, deep-learning embryo selection in IVF failed to
meet non-inferiority against manual morphology, which is a prospective negative
for a deployed clinical AI rather than a benchmark result; and
39054373 (Nat Med) — identical
medical advice was rated worse when patients were told AI was involved, a barrier
to deployment that no improvement in accuracy touches. With the generalist
vision–language model in section 3, foundation-models closes +2 / −3.
39348147 (JAMA) — a pragmatic
randomised trial of Helicobacter pylori screening to prevent gastric cancer was
null in intention-to-treat. interception's claim is that acting on the precursor
changes the outcome, and this is that claim tested at population scale and not
supported. 39562005 (JITC) — a
B7-H3-targeting nanobody CAR-T shows on-target off-tumour toxicity that
antigen-sensitivity tuning only partly avoids.
39385035 (Nature) is the odd one:
adding CTLA-4 blockade abrogates the resistance to PD-(L)1 inhibition associated
with KEAP1/STK11 alterations. It is carded against immunotherapy-resistance
because genotype-defined resistance turns out not to be fixed — which is a good
result for patients and a refutation of the thread's premise at the same time.
(b) Method credibility¶
November 2024 takes twenty cards here, +3 / −17, against November 2025's seventeen. Across the corpus this thread's largest month is January 2024 at thirty. The 2024 monthly counts run between five and thirty with a median of 14.5; the 2025 counts run between nine and twenty-two with a median of sixteen. Those two distributions are not distinguishable by eye or by any reading this corpus supports. So the visible difference between November 2024 and November 2025 in this file is mostly a difference in how hard each month was read, which is the error the whole corpus has been correcting for.
Three of the twenty are supports, which on a thread reading crisis is worth
naming: applying the competing WHO and ICC lymphoma classifications to real-world
cases changes assignment in under 1% of them
39255410 (Blood); the Stockholm3
prostate risk score validates prospectively in a multiethnic cohort, beyond the
population it was trained on 39038251
(JCO); and the HLH-2004 diagnostic criteria, re-examined against real cases,
perform as intended 39046779
(Blood). That is the most passes this ledger has recorded in a single month up
to this point.
Corrected 2026-09-04
This paragraph carried three wrong numbers. It said November 2024 "is thin here" — it takes twenty cards, which is above the 2024 median. It said November 2025 takes ten cards and is this thread's largest month — November 2025 takes seventeen, and the largest month is January 2024 at thirty. And it put the 2024 monthly counts "between one and eight with a median of three"; they run between five and thirty with a median of 14.5. All three came from the title-only reading of 2024, which the abstract re-scan of 2026-09-04 replaced. The paragraph's argument is unchanged and is now better supported than when it was written: the two Novembers are twenty cards and seventeen, and the gap that looked like a change in the literature was a gap in the reading.
5. Open items¶
Nothing carried forward.
6. Meetings¶
No abstract book published this month. The abstract layer runs 2023-02 to 2026-08 and is seasonal by nature — meetings are annual, so most months are empty here and that is the expected shape, not a gap in the harvest.
7. Regulatory¶
| Event | Count |
|---|---|
| trial-first-posted | 439 (of which 401 genuinely oncology) |
| ema-authorisation | 9 |
| fda-approval | 4 |
4 FDA actions — dated from each notice's own prose, not the table's posting date, which disagrees on 7 of 190 rows and once by enough to move an approval into the wrong month:
- 2024-11-08 — FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
- 2024-11-15 — FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation
- 2024-11-19 — FDA approves updated drug labeling for fludarabine phosphate under Project Renewal
- 2024-11-20 — FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer
2 EMA oncology authorisations:
- 2024-11-14 — Pomalidomide Teva
- 2024-11-14 — Elahere
8. Trade press¶
34 on-topic of 283 items across 3 feeds (n-stat 273, n-aacr-blog 8, n-acir 2). Headlines are selected by subject keyword, not recency — most of what these feeds carry is health policy and industry finance the corpus does not read.
- 2024-11-29 — Opinion: A new moonshot initiative to fight cervical cancer in the Indo-Pacific region is missing something —
n-stat - 2024-11-27 — Early-career Cancer Researchers Interview NCI Director Kimryn Rathmell —
n-aacr-blog - 2024-11-26 — STAT+: Roche immunotherapy fails in lung cancer study, raising questions about drug’s target —
n-stat - 2024-11-25 — STAT+: Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial —
n-stat - 2024-11-23 — STAT+: BridgeBio wins FDA approval for heart disease drug —
n-stat - 2024-11-22 — Opinion: Why cancer advocates like me are leaving X —
n-stat - 2024-11-21 — STAT+: Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment —
n-stat - 2024-11-20 — STAT+: Kura licenses leukemia drug to Japanese drugmaker —
n-stat - 2024-11-20 — STAT+: Doubling down on its strategy, Pfizer names its head of oncology as new research chief —
n-stat - 2024-11-19 — Cancer Discovery Explores New Horizons for Cancer Research in China —
n-aacr-blog - 2024-11-18 — STAT+: Syndax wins U.S. approval for leukemia treatment —
n-stat - 2024-11-18 — STAT+: Regenxbio says gene therapy strengthened boys with Duchenne muscular dystrophy —
n-stat - … and 22 more on-topic items.